In this respect, despite the undeniable immunological effects of adjuvant IL-2 in subjects with poor CD4+ recovery on cART [24], this strategy was abandoned for the treatment of HIV infection, given it failed to provide clinical benefit compared to antiretrovirals alone [25]. This evidence concerns the gene CD4 and HIV infectious disease.